Atara Biotherapeutics (ATRA) Asset Utilization Ratio (2021 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Asset Utilization Ratio came in at 0.3 in Q2 2026, down 92.08% on a YoY basis from 3.81 in Q2 2025, and down 73.75% quarter-over-quarter from 1.15 in Q1 2026.
Powered by 
Analysis
Atara Biotherapeutics (ATRA) Asset Utilization Ratio (2021 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has reported Asset Utilization Ratio for 6 consecutive years, with 0.3 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Asset Utilization Ratio fell 92.08% year-over-year to 0.3; the trailing twelve-month figure through Jun 2026 stood at 0.3 (down 92.08% YoY), and the FY2025 full-year result was 1.87, up 98.87% from the prior year.
- Asset Utilization Ratio slipped to 0.3 in Q2 2026 per ATRA's latest filing, from 1.15 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 4.79 in Q4 2025 and bottomed at 0.02 in Q3 2023.
- Historically, Asset Utilization Ratio has averaged 1.12 across 5 years, with a median of 0.26 in 2026.
- The sharpest annual moves came in 2024 and 2026: Asset Utilization Ratio jumped 3579.94% in 2024, then slumped 92.08% in 2026.
- Over 5 years, Asset Utilization Ratio stood at 0.17 in 2022, then slumped by 71.67% to 0.05 in 2023, then surged by 2016.18% to 1.02 in 2024, then jumped by 367.94% to 4.79 in 2025, then slumped by 93.7% to 0.3 in 2026.
- According to Business Quant data, Asset Utilization Ratio over the past three periods registered 0.3, 1.15, and 4.79 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 0.30 |
| 2 | CRISPR Therapeutics AG | 5.04 Bn | 5.04 Bn | - | 0.00 |
| 3 | Iovance Biotherapeutics | 3.65 Bn | 3.36 Bn | 55.72 Mn | 0.35 |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 0.76 |
| 5 | uniQure | 2.95 Bn | 2.95 Bn | 5.49 Mn | 0.02 |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - | 0.11 |
| 7 | Precigen | 2.39 Bn | 2.39 Bn | 52.17 Mn | 0.55 |
| 8 | Sarepta Therapeutics | 2.16 Bn | 1.37 Bn | 251.87 Mn | 0.62 |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 0.62 |
| 10 | Atara Biotherapeutics | 148.00 Mn | 131.45 Mn | 439,000.00 | 0.30 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 0.30 |
| Mar 31, 2026 | 1.15 |
| Dec 31, 2025 | 4.79 |
| Sep 30, 2025 | 4.53 |
| Jun 30, 2025 | 3.81 |
| Mar 31, 2025 | 2.33 |
| Dec 31, 2024 | 1.02 |
| Sep 30, 2024 | 0.77 |
| Jun 30, 2024 | 0.44 |
| Mar 31, 2024 | 0.21 |
| Dec 31, 2023 | 0.05 |
| Sep 30, 2023 | 0.02 |
| Jun 30, 2023 | 0.03 |
| Mar 31, 2023 | 0.17 |
| Dec 31, 2022 | 0.17 |
| Sep 30, 2022 | 0.18 |
| Jun 30, 2022 | 0.17 |
| Mar 31, 2022 | 0.06 |
| Dec 31, 2021 | 0.04 |
| Sep 30, 2021 | 0.03 |